Brexit has given UK scope for free trade, its own regulations and control of immigration

The article argues Brexit could add roughly 6% to UK GDP in the long run through freer trade and another 6% through more pragmatic regulation, though realization may take a decade or more. It highlights ongoing UK FTAs with CPTPP members, Australia, New Zealand, India and the US, plus greater regulatory flexibility in drugs, AI and the City. Immigration has also remained open, with net inflows rising post-Brexit, supporting labor supply and offsetting aging demographics.

Analysis

The investable implication is not “Brexit worked,” but that the UK is slowly building an idiosyncratic policy regime that widens dispersion within domestic cyclicals and between UK- and EU-facing franchises. The first-order beneficiaries are companies with high regulatory optionality and low dependence on continental standards—UK-listed biotech, AI/software, exchanges, specialist financials, and legal/regulatory service providers—because incremental rule-making flexibility lowers time-to-market and raises the value of experimentation. The second-order losers are firms whose economics depended on passive access to EU labor, EU-standard compliance, or protected domestic incumbency; margins may not collapse, but capex and compliance burdens should stay structurally lower for the more adaptive peer set.

The more important catalyst is political rather than economic: the market will likely price this as a series of small regime changes over 12-36 months, not a single Brexit payoff. That creates a classic underappreciated timing issue—near-term data can look mediocre while the option value of policy divergence compounds later. Conversely, any change in government rhetoric around labor rights, food standards, or de facto alignment with EU rules would compress the spread quickly, especially for names already priced for a lighter-touch UK regime.

The contrarian angle is that consensus may be underestimating how much of the “gain” is already embedded in UK assets as a governance discount story, while overestimating the immediate macro uplift. The real alpha is in relative winners that monetize discretion and innovation, not in broad UK GDP beta. Immigration policy is the least clean trade: it supports labor supply over time, but also keeps wages and consumer demand from tightening too much, which is mildly supportive for domestic services and residential housing rather than pure labor arbitrage plays.

Key Decisions for Investors

• Long UK domestic innovation basket vs EU-regulated peers: buy AMS.L / HLN.L / CTEC.L on 6-12 month horizon; avoid relying on headline GDP, instead underwrite to faster product approval and lower compliance drag. Risk: policy reversal or renewed EU alignment rhetoric.
• Pair trade: long LSE.L and/or 3i infrastructure-adjacent UK financial infrastructure names vs short EU-exposed market infrastructure/clearing proxies over 6-9 months. Thesis: regulatory divergence increases UK franchise value and pricing power. Stop if UK rulemaking starts converging back toward EU norms.
• Initiate long UK mid-cap healthcare/biotech optionality via proprietary baskets or names like AZN.L and smaller UK innovators on 12-24 month horizon. Best asymmetric exposure is to faster UK approval cycles and AI/drug-development permissiveness. Risk/reward favors call spreads over cash equity due to policy lag.
• Short UK labor-intensity beneficiaries with weak pricing power if labor regulation tightens further: focus on staffing, low-margin hospitality, and logistics names for a 3-6 month tactical trade. Use a basket rather than single-name shorts to avoid idiosyncratic deal risk.
• Maintain a modest long GBP tilt only on pullbacks, but hedge with FTSE 100 exporters; the real trade is UK domestic dispersion, not currency directional risk. If markets start pricing a credible UK productivity regime, domestic small/mid caps should outperform the index by 5-10% over the next 12 months.